Comprehensive Safety Exposure-Response Analysis to Support Ritlecitinib Dose Selection

May 2025 in “ CPT Pharmacometrics & Systems Pharmacology ”

Yeamin Huh, Ruolun Qiu, John P. Prybylski, Jessica Wojciechowski, Yuchen Wang, Vivek S. Purohit

ritlecitinib alopecia areata kinase inhibitor QTc prolongation lymphocytes lymphopenia infections rash

Studysummary This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study evaluated the safety profile of ritlecitinib, a kinase inhibitor for treating alopecia areata, through a comprehensive safety exposure-response analysis involving 1,744 subjects. The analysis found no ritlecitinib-induced QTc prolongation and minimal changes in lymphocyte counts, with a low incidence of Grade 3/4 lymphopenia. The study supported a 50 mg non-loading dose regimen for both adults and adolescents, showing a favorable benefit-risk profile. The findings indicated that adverse events were more related to baseline characteristics than drug exposure, and the safety profile was consistent across different patient subgroups. The results were accepted by regulatory agencies, including the FDA, supporting the dose selection without the need for a TQT study.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

6 / 6 results

research Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1)

63 citations , July 2024 in “Journal of the American Academy of Dermatology”

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm

research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm

5 citations , February 2024 in “Clinical Pharmacokinetics”

This study found that modeling and simulation effectively informed decision-making and dose selection for ritlecitinib in treating alopecia areata, supporting an accelerated drug development strategy.

research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development

6 citations , November 2023 in “Clinical Pharmacokinetics”

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial

227 citations , April 2023 in “The Lancet”

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents

28 citations , December 2017 in “Journal of Investigative Dermatology Symposium Proceedings”

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.